Market capitalization | GBP1.05b |
Enterprise Value | GBP1.05b |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 9.92 |
EV/Sales (TTM) EV/Sales | 1.15 |
P/S ratio (TTM) P/S ratio | 1.15 |
P/B ratio (TTM) P/B ratio | negative |
Revenue growth (TTM) Revenue growth | 2.47% |
Revenue (TTM) Revenue | GBP916.88m |
As a Free StocksGuide user, you can view scores for all 6,790 stocks worldwide.
7 Analysts have issued a Indivior forecast:
7 Analysts have issued a Indivior forecast:
Mar '25 |
+/-
%
|
||
Revenue | 917 917 |
2%
2%
|
|
Gross Profit | 759 759 |
5%
5%
|
|
EBITDA | 239 239 |
558%
558%
|
EBIT (Operating Income) EBIT | 220 220 |
1,776%
1,776%
|
Net Profit | -29 -29 |
668%
668%
|
In millions GBP.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Indivior PLC is a holding company, which engages in the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence. Its products include Suboxone Film, Suboxone Tablet, and Subutex Tablet. It operates through the following geographical segments: United States, Rest of World, and United Kingdom. The company was founded on September 26, 2014 and is headquartered in Slough, the United Kingdom.
Head office | United Kingdom |
CEO | Joseph Ciaffoni |
Employees | 1,051 |
Founded | 2014 |
Website | indivior.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.